Rituximab in ANCA-associated vasculitis: Fad or fact?

Fernando C. Fervenza

doi:10.1159/000321437

Rituximab in ANCA-associated vasculitis: Fad or fact?

Fernando C. Fervenza

Nephrology and Hypertension

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

A number of case reports and case series of patients with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, recently published in the New England Journal of Medicine, have examined the efficacy of RTX in inducing remission in patients with severe AAV.

Original language	English (US)
Pages (from-to)	c182-c188
Journal	Nephron - Clinical Practice
Volume	118
Issue number	2
DOIs	https://doi.org/10.1159/000321437
State	Published - May 1 2011

Keywords

Cyclophosphamide
High-dose glucocorticosteroids
Rituximab

ASJC Scopus subject areas

Nephrology

Access to Document

10.1159/000321437

Fingerprint Dive into the research topics of 'Rituximab in ANCA-associated vasculitis: Fad or fact?'. Together they form a unique fingerprint.

Cite this

@article{1366f14f1af148deb0d61dba0377c122,

title = "Rituximab in ANCA-associated vasculitis: Fad or fact?",

abstract = "A number of case reports and case series of patients with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, recently published in the New England Journal of Medicine, have examined the efficacy of RTX in inducing remission in patients with severe AAV.",

keywords = "Cyclophosphamide, High-dose glucocorticosteroids, Rituximab",

author = "Fervenza, {Fernando C.}",

year = "2011",

month = may,

day = "1",

doi = "10.1159/000321437",

language = "English (US)",

volume = "118",

pages = "c182--c188",

journal = "Nephron - Clinical Practice",

issn = "1660-2110",

number = "2",

}

TY - JOUR

T1 - Rituximab in ANCA-associated vasculitis

T2 - Fad or fact?

AU - Fervenza, Fernando C.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - A number of case reports and case series of patients with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, recently published in the New England Journal of Medicine, have examined the efficacy of RTX in inducing remission in patients with severe AAV.

AB - A number of case reports and case series of patients with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, recently published in the New England Journal of Medicine, have examined the efficacy of RTX in inducing remission in patients with severe AAV.

KW - Cyclophosphamide

KW - High-dose glucocorticosteroids

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=78650072277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650072277&partnerID=8YFLogxK

U2 - 10.1159/000321437

DO - 10.1159/000321437

M3 - Review article

C2 - 21160229

AN - SCOPUS:78650072277

VL - 118

SP - c182-c188

JO - Nephron - Clinical Practice

JF - Nephron - Clinical Practice

SN - 1660-2110

IS - 2

ER -